Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Stock Editorial via Getty Images An expert panel of the EU drug regulator, the European Medicines Agency (EMA), has ...

Ro, a telehealth company, has teamed up with Eli Lilly to improve patient access to Zepbound (tirzepatide). Through ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

Zacks Research analyst K. Shah now forecasts that the company will post earnings of $4.69 per share for the quarter, down from […] ...

Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable single-dose vials of the weight-loss drug Zepbound, streamlining access through a seamless platform. The ...

Eli Lilly has partnered with the telehealth company Ro to expand access to single-dose vials of its popular weight loss drug Zepbound. Through Ro's platform, eligible patients can receive ...

The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...

Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an ...

Eli Lilly ( LLY -1.72%) may seem like an expensive stock to invest in right now. It's trading at close to 90 times its ...